Collaborative efforts driving progress in pediatric acute myeloid leukemia

Journal of Clinical Oncology

Volumn 33, Issue 27, 2015, Pages 2949-2962

  Zwaan, C Michel ^a,b,c,d   Kolb, Edward A ^h,i   Reinhardt, Dirk ^j,l   Abrahamsson, Jonas ^m,n   Adachi, Souichi ^o,p   Aplenc, Richard ^i,r   De Bont, Eveline S J M ^d,e   De Moerloose, Barbara ^s   Dworzak, Michael ^l,t   Gibson, Brenda E S ^u,v   Hasle, Henrik ^l,n,w   Leverger, Guy ^x   Locatelli, Franco ^y,z   Ragu, Christine ^x   Ribeiro, Raul C ^ab   Rizzari, Carmelo ^z,aa   Rubnitz, Jeffrey E ^ab   Smith, Owen P ^v,ac   Sung, Lillian ^i,ad   Tomizawa, Daisuke ^q   Van Den Heuvel Eibrink, Marry M ^a,d,f   Creutzig, Ursula ^k,l   Kaspers, Gertjan J L ^d,f,g,l   more..

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b International Berlin Frankfurt Münster Study Group I BFM SG New Agents Committee   (Germany)

^c Innovative Therapies for Children with Cancer Consortium ^*  (Germany)

^d DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f University Medical Center Utrecht Princess Máxima Center for Pediatric Oncology   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

ⁱ CHILDREN S ONCOLOGY GROUP   (United States)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l I BFM AcuteMyeloid Leukemia (AML) Study Group   (Germany)

^m SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ Karolinska Hospita   (Sweden)

^o KYOTO UNIVERSITY   (Japan)

^p Japanese Pediatric Leukemia/Lymphoma Study Group   (Japan)

^q NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^r CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^s GHENT UNIVERSITY HOSPITAL   (Belgium)

^t MEDICAL UNIVERSITY OF VIENNA   (Austria)

^u ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^v UK Children's Cancer Study Group   (United Kingdom)

^w AARHUS UNIVERSITY HOSPITAL   (Denmark)

^x SORBONNE UNIVERSITÉ   (France)

^y UNIVERSITY OF PAVIA   (Italy)

^z Childhood AML Working Party AIEOP   (Italy)

^aa SAN GERARDO HOSPITAL   (Italy)

^ab ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^ac OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^ad HOSPITAL FOR SICK CHILDREN   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTILEUKEMIC AGENT; CYTARABINE;

ACUTE MYELOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CONSOLIDATION CHEMOTHERAPY; DOWN SYNDROME; DRUG MEGADOSE; HEALTH CARE QUALITY; HIGH RISK POPULATION; HISTORY OF MEDICINE; HUMAN; LEUKEMIA RELAPSE; MAINTENANCE CHEMOTHERAPY; MULTIMODALITY CANCER THERAPY; MYELOID LEUKEMIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; TRANSLATIONAL RESEARCH; ADOLESCENT; ADULT; CHILD; COOPERATION; DISEASE FREE SURVIVAL; HISTORY; INFANT; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; LEUKEMIA, MYELOID, ACUTE; MASS COMMUNICATION; MORTALITY; NEWBORN; ONCOLOGY; ONSET AGE; PEDIATRICS; PRESCHOOL CHILD; RISK FACTOR; SURVIVOR; TIME; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; CHILD; CHILD, PRESCHOOL; COOPERATIVE BEHAVIOR; DIFFUSION OF INNOVATION; DISEASE-FREE SURVIVAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFANT; INFANT, NEWBORN; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; LEUKEMIA, MYELOID, ACUTE; MEDICAL ONCOLOGY; PEDIATRICS; RISK FACTORS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942279743     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.8289     Document Type: Review

References (149)

1. Creutzig U, Van Den Heuvel-Eibrink MM, Gibson B, et al: Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood 120:3167-3205, 2012
2. Kaspers GJL: Pediatric acute myeloid leukemia. Expert Rev Anticancer Ther 12:405-413, 2012
3. Pui C-H, Carroll WL, Meshinchi S, et al: Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 29:551- 565, 2011
4. Abrahamsson J, Forestier E, Heldrup J, et al: Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol 29:310-315, 2011
5. Cooper TM, Franklin J, Gerbing RB, et al: AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group. Cancer 118:761-769, 2012
6. Creutzig U, Zimmermann M, Bourquin JP, et al: Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from study AML-BFM 2004. Blood 122:37-43, 2013
7. Dluzniewska A, Balwierz W, Armata J, et al: Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia 19:2117-2124, 2005
8. Entz-Werle N, Suciu S, van der Werfften BJ, et al: Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: The EORTC Children Leukemia Group report. Leukemia 19:2072-2081, 2005
9. Gamis AS, Alonzo TA, Meshinchi S, et al: Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase III Children's Oncology Group Trial AAML0531. J Clin Oncol 32: 3021-3032, 2014
10. Gibson BES, Webb DKH, Howman AJ, et al: Results of a randomized trial in children with acute myeloid leukemia: Medical Research Council AML12 trial. Br J Haematol 155:366-376, 2011
11. Pession A, Masetti R, Rizzari C, et al: Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 122:170-178, 2013
12. Rubnitz JE, Inaba H, Dahl G, et al: Minimal residual disease-directed therapy for childhood acute myeloid leukemia: Results of the AML02 multicentre trial. Lancet Oncol 11:543-552, 2010
13. Tomizawa D, Tawa A, Watanabe T, et al: Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: A report from the Japanese pediatric leukemia/lymphoma study group. Int J Hematol 98:578-588, 2013
14. Tomizawa D, Tawa A, Watanabe T, et al: Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. Leukemia 27:2413-2416, 2013
15. Tsukimoto I, Tawa A, Horibe K, et al: Riskstratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese childhood AML cooperative study group. J Clin Oncol 27:4007-4013, 2009
16. Hasle H, Abrahamsson J, Forestier E, et al: Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: Results from NOPHO-AML 2004. Blood 120:978- 984, 2012
17. Vogelstein B, Papadopoulos N, Velculescu VE, et al: Cancer genome landscapes. Science 339: 1546-1558, 2013
18. Kelly LM, Gilliland DG: Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3:179-198, 2002
19. Hollink IHIM, Zwaan CM, Zimmermann M, et al: Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 23:262-270, 2009
20. Brown P, Mcintyre E, Rau R, et al: The incidence and clinical significance of nucleophosmin mutations in childhood AML. Hematology 979-985, 2008
21. Ho PA, Alonzo TA, Gerbing RB, et al: Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group. Blood 113:6558-6566, 2009
22. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al: Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica 96:384-392, 2011
23. Matsuo H, Kajihara M, Tomizawa D, et al: Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Blood Cancer J 4:e226, 2014
24. Mrózek K, Bloomfield CD: Chromosome aberrations, gene mutations, and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 169-177, 2006
25. Zwaan CM, Meshinchi S, Radich JP, et al: FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: Prognostic significance and relation to cellular drug resistance. Blood 102:2387-2394, 2003
26. Meshinchi S, Alonzo TA, Stirewalt DL, et al: Clinical implications of FLT3 mutations in pediatric AML. Blood 108:3654-3661, 2006
27. Cloos J, Goemans BF, Hess CJ, et al: Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 20:1217-1220, 2006
28. Bachas C, Schuurhuis GJ, Hollink IHIM, et al: High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: Implications for personalized medicine. Blood 116:2752-2758, 2010
29. Smith CC, Wang Q, Chin C, et al: Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia. Nature 485:260- 263, 2012
30. Meshinchi S, Stirewalt DL, Alonzo Ta, et al: Structural and numerical variation of FLT3/ITD in pediatric AML: Brief report. Blood 4930-4933, 2012
31. Balgobind BV, Raimondi SC, Harbott J, et al: Novel prognostic subgroups in childhood 11q23/ MLL-rearranged acute myeloid leukemia: Results of an international retrospective study. Cancer 114: 2489-2496, 2009
32. Meyer C, Hofmann J, Burmeister T, et al: The MLL recombinome of acute leukemias in 2013. Leukemia 27:2165-2176, 2013
33. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al: NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. 118:3645-3656, 2011
34. Ostronoff F, Othus M, Gerbing RB, et al: NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: A COG and SWOG report. Blood 124:2400-2408, 2015
35. de Rooij JD, Hollink IH, Arentsen-Peters ST, et al: NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia 27:2280-2288, 2013
36. Reinhardt D, Diekamp S, Langebrake C, et al: Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: Improved outcome with intensified induction treatment. Leukemia 19:1495-1496, 2005
37. O'Brien MM, Cao X, Pounds S, et al: Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: A report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421. Leukemia 731-734, 2012
38. Masetti R, Pigazzi M, Togni M, et al: CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood 121:3469-3472, 2013
39. Gruber TA, Gedman AL, Zhang J, et al: An inv(16)(p13.3q24.3) - encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 22:683-697, 2012
40. Von Bergh ARM, Van Drunen E, Van Wering ER, et al: High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9. Genes Chromosomes Cancer 45:731-739, 2006
41. Sandahl JD, Coenen EA, Forestier E, et al: T(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: An international study of 62 patients. Haematologica 99:865-872, 2014
42. Tarlock K, Alonzo TA, Moraleda PP, et al: Acute myeloid leukemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: A report from the Children's Oncology Group. Br J Haematol 166:254- 259, 2014
43. Coenen EA, Zwaan CM, Reinhardt D, et al: Pediatric acute myeloid leukemia with t(8;16)(p11; p13), a distinct clinical and biological entity: A collaborative study by the International Berlin-Frankfurt- Munster AML study group. Blood 122:2704-2713, 2013
44. Linch DC, Hills RK, Burnett AK, et al: Impact of FLT3 ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia Impact of FLT3 ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood 124:273-276, 2014
45. Walter RB, Othus M, Burnett AK, et al: Resistance prediction in AML: Analysis of 4,601 patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. Leukemia 29:312- 320, 2015
46. Pratcorona M, Brunet S, Nomdedéu J, et al: Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: Relevance to post-remission therapy. Blood 121:2734- 2738, 2013
47. Hollink IH, Van den Heuvel-Eibrink MM, Zimmermann M, et al: Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 113:5951-5960, 2009
48. Ho PA, Alonzo TA, Gerbing RB, et al: Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group. Blood 116: 702-710, 2010
49. Balgobind BV, Lugthart S, Hollink IH, et al: EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia 24:942-949, 2010
50. Ho PA, Alonzo TA, Gerbing RB, et al: High EVI1 Expression is associated with MLL rearrangements and predicts decreased survival in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Br J Haematol 162:670-677, 2013
51. Matsuo H, Kajihara M, Tomizawa D, et al: EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. Haematologica 99:e225-e227, 2014
52. Hasle H, Alonzo TA, Auvrignon A, et al: Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: An international retrospective study. Blood 109:4641-4647, 2007
53. Balgobind BV, Hollink IH, Arentsen-Peters ST, et al: Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica 96:1478-1487, 2011
54. Berman JN, Gerbing RB, Alonzo TA, et al: Prevalence and clinical implications of NRAS mutations in childhood AML: A report from the Children's Oncology Group. Leukemia 25:1039-1042, 2011
55. Meshinchi S, Stirewalt D: Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 102:1474-1479, 2003
56. Burgess MR, Hwang E, Firestone AJ, et al: Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood 124:3947-3955, 2014
57. Kampen KR, Ter Elst A, Mahmud H, et al: Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML. Leukemia 28:589-599, 2013
58. Meshinchi S, Thomson B, Finn LS, et al: Comparison of multidimensional flow cytometry with standard morphology for evaluation of early marrow response in pediatric acute lymphoblastic leukemia. J Pediatr Hematol 23:585-590, 2001
59. van der Velden VH, van der Sluijs-Geling A, Gibson BE, et al: Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 24:1599-1606, 2010
60. Sievers EL, Lange BJ, Alonzo TA, et al: Immunophenotypic evidence of leukemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 101: 3398-3406, 2003
61. Loken MR, Alonzo TA, Pardo L, et al: Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: A report from Children's Oncology Group. Blood 120:1581-1588, 2012
62. Inaba H, Coustan-Smith E, Cao X, et al: Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 30:3625-3632, 2012
63. Ommen HB, Schnittger S, Jovanovic JV, et al: Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFBMYH11 acute myeloid leukemias. Blood 115:198- 205, 2010
64. Creutzig U, Zimmermann M, Ritter J, et al: Treatment strategies and long-term results in pediatric patients treated in four consecutive AML-BFM trials. Leukemia 19:2030-2042, 2005
65. Mandelli F, Vignetti M, Suciu S, et al: Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA groups study AML-10. J Clin Oncol 27: 5397-5403, 2009
66. Löwenberg B, Ossenkoppele GJ, van Putten W, et al: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361: 1235-1248, 2009
67. Lee JH, Joo YD, Kim H, et al: A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 118:3832-3841, 2011
68. Armenian SH, Hudson MM, Mulder RL, et al: Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16: e123-e136, 2015
69. Burnett AK, Russell NH, Hills RK, et al: Optimization of chemotherapy for younger patients with acute myeloid leukemia: Results of the medical research council AML15 trial. J Clin Oncol 31:3360- 3368, 2013
70. Bishop JF: Approaches to induction therapy with adult acute myeloid leukemia. Acta Haematol 99:133-137, 1998
71. Weick BJK, Kopecky KJ, Appelbaum FR, et al: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood 88:2841-2851, 1996
72. Ravindranath Y, Chang M, Steuber CP, et al: Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:2101-2116, 2005
73. Creutzig U, Zimmermann M, Bourquin JP, et al: Second induction with high-dose cytarabine and mitoxantrone: Different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 118: 5409-5415, 2011
74. Burnett AK, Hills RK, Milligan D, et al: Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 Trial. J Clin Oncol 29:369-377, 2011
75. Burnett AK, Russell NH, Hills RK, et al: Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30:3924- 3931, 2012
76. Castaigne S, Pautas C, Terré C, et al: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomized, open-label, phase 3 study. Lancet 379:1508-1516, 2012
77. Tomizawa D, Tabuchi K, Kinoshita A, et al: Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML Treated on two consecutive trials of Tokyo Children's Cancer Study Group. Pediatr Blood Cancer 49:127-132, 2007
78. Harrison CJ, Hills RK, Moorman AV, et al: Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. J Clin Oncol 28:2674- 2681, 2010
79. Perel Y, Auvrignon a, Leblanc T, et al: Treatment of childhood acute myeloblastic leukemia: Dose intensification improves outcome and maintenance therapy is of no benefit - Multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Leukemia 19: 2082-2089, 2005
80. Kaspers G: How I treat pediatric relapsed acute myeloid leuaemia. Br J Haematol 166:636- 645, 2014
81. Lange, Beverly J, Yang RK, Gan J, et al: Soluble Interleukin-2 receptor a activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia. Pediatr Blood Cancer 57:398-405, 2011
82. Kaspers GJL, Zimmermann M, Reinhardt D, et al: Improved outcome in pediatric relapsed acute myeloid leukemia: Results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 31:599-607, 2013
83. Pui C-H, Schrappe M, Ribeiro RC, et al: Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program 118-145, 2004
84. Kaspers GJ, Creutzig U: Pediatric acute myeloid leukemia: International progress and future directions. Leukemia 19:2025-2029, 2005
85. Abbott BL, Rubnitz JE, Tong X, et al: Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: A single institution's experience. Leukemia 17:2090-2096, 2003
86. Pui CH, Howard SC: Current management and challenges of malignant disease in the CNS in pediatric leukemia. Lancet Oncol 9:257-268, 2008
87. Creutzig U, Reinhardt D: Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? A European view. Br J Haematol 118:365-377, 2002
88. Chen AR, Alonzo TA, Woods WG, et al: Current controversies: Which patients with acute myeloid leukemia should receive a bone marrow transplantation? An American view. Br J Haematol 118:378-384, 2002
89. Bleakley M, Lau L, Shaw PJ, et al: Acute myeloid leukemia bone marrow transplantation for pediatric AML in first remission: A systematic review and meta-analysis. Bone Marrow Transplant 29:843-852, 2002
90. Niewerth D, Creutzig U, Bierings MB, et al: A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 116:2205-2214, 2010
91. Hasle H: A critical review of which children with acute myeloid leukemia need stem cell procedures. Br J Haematol 166:23-33, 2014
92. Leung W, Pui CH, Coustan-Smith E, et al: Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 120:468-472, 2012
93. Goemans BF, Tamminga RY, Corbijn CM, et al: Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: Survival after chemotherapy only? Haematologica 93:1418-1420, 2008
94. Beier R, Albert MH, Bader P, et al: Allo-SCT using BU, CY, and melphalan for children with AML in second CR. Bone Marrow Transplant 651-656, 2012
95. Testi AM, Biondi A, Lo Coco F, et al: GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 106:447-453, 2005
96. Gregory J, Kim H, Alonzo T, et al: Treatment of children with acute promyelocytic leukemia: Results of the first North American Intergroup Trial INT0129. Pediatr Blood Cancer 53:1005-1010, 2009
97. Soignet SL, Maslak P, Wang Z-G, et al: Complete remission after treatment of acute promyelocytic leukemia. N Engl J Med 339:1341-1348, 1998
98. Mathews V, George B, Chendamarai E, et al: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term follow-up data. J Clin Oncol 28:3866- 3871, 2010
99. Lo-Coco F, Avvisati G, Vignetti M, et al: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111-121, 2013
100. Zwaan CM, Reinhardt D, Hitzler J, et al: Acute leukemias in children with Down syndrome. Hematol Oncol Clin North Am 24:19-34, 2010
101. Sorrell AD, Alonzo TA, Hilden JM, et al: Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: A report from the Children's Oncology Group. Cancer 118:4806-4814, 2012
102. Kudo K, Kojima S, Tabuchi K, et al: Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: The Japanese childhood AML cooperative study group. J Clin Oncol 25:5442-5447, 2007
103. Creutzig U, Reinhardt D, Diekamp S, et al: AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 19:1355-1360, 2005
104. Taga T, Saito AM, Kudo K, et al: Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood 120:1810-1815, 2012
105. Webb DK, Wheatley K, Harrison G, et al: Outcome for children with relapsed acute myeloid leukemia following initial therapy in the Medical Research Council (MRC) AML 10 trial: MRC Childhood Leukemia Working Party. Leukemia 13:25-31, 1999
106. Sander A, Zimmermann M, Dworzak M, et al: Consequent and intensified relapse therapy improved survival in pediatric AML: Results of relapse treatment in 379 patients of three consecutive AMLBFM trials. Leukemia 24:1422-1428, 2010
107. Cooper TM, Alonzo TA, Gerbing RB, et al: AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer 120:2482-2489, 2014
108. Horton TM, Perentesis JP, Gamis AS, et al: A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 61:1754- 1760, 2014
109. Gorman M: Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A Therapeutic Advances in Childhood Leukemia (TACL) consortium study. Pediatr Blood Cancer 55:421-429, 2010
110. Nakayama H, Tabuchi K, Tawa A, et al: Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol. Int J Hematol 100:171-179, 2014
111. Creutzig U, Zimmermann M, Dworzak MN, et al: The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: Results of the international study Relapsed AML 2001/01. Haematologica 99:1472-1478, 2014
112. Moore AS, Kearns PR, Knapper S, et al: Novel therapies for children with acute myeloid leukemia. Leukemia 27:1451-1460, 2013
113. Tasian SK, Pollard JA, Aplenc R: Molecular therapeutic approaches for pediatric acute myeloid leukemia. Front Oncol 4:55, 2014
114. Shukla N, Kobos R, Renaud T, et al: Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. Pediatr Blood Cancer 61:431- 435, 2014
115. Lancet JE, Cortes JE, Hogge DE, et al: Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/ daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 123:3239- 3246, 2014
116. Lancet JE, Roboz GJ, Cripe LD, et al: A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica 100:231-237, 2014
117. Zwaan CM, Reinhardt D, Corbacioglu S, et al: Gemtuzumab ozogamicin: First clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 101:3868-3871, 2003
118. Zwaan CM, Reinhardt D, Zimmerman M, et al: Salvage treatment for children with refractory first or second relapse of acute myeloid leukemia with gemtuzumab ozogamicin: Results of a phase II study. Br J Haematol 148:768-776, 2010
119. Laszlo GS, Gudgeon CJ, Harrington KH, et al: Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 123:554-561, 2014
120. Röllig C, Müller-Tidow C, Hüttmann A, et al: Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: Results from 267 patients treated in the randomized placebo-controlled SALSoraml trial. Presented at the American Society of Hematology Annual Meeting, San Francisco, CA, December 6-9, 2014 (abstr 6)
121. Galanis A, Ma H, Rajkhowa T, et al: Crenolanib is a potent inhibitor of flt3 with activity against resistance-conferring point mutants. Blood 123:94- 100, 2014
122. Goemans BF, Zwaan CM, Miller M, et al: Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19:1536-1542, 2005
123. Pollard JA, Alonzo TA, Gerbing RB, et al: Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 115:2372-2379, 2010
124. Manara E, Bisio V, Masetti R, et al: Corebinding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: Screening and prognostic impact of c-KIT mutations. Leukemia 28:1132-1134, 2014
125. Shimada A, Taki T, Tabuchi K: KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): A study of the Japanese Childhood AML Cooperative Study Group. Blood 107:1806-1809, 2006
126. Jain N, Curran E, Iyengar NM, et al: Phase 2 study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: A University of Chicago phase 2 consortium trial. Clin Cancer Res 20:490-498, 2014
127. Döhner H, Lübbert M, Fiedler W, et al: Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood 1426- 1434, 2014
128. Kantarjian HM, Martinelli G, Jabbour EJ, et al: Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer 119: 2611-2619, 2013
129. Stewart AK, Rajkumar SV, Dimopoulos MA, et al: Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372: 142-152, 2015
130. Stumpel D, Schneider P, Seslija L, et al: Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia 26:682-692, 2012
131. Daigle SR, Olhava EJ, Therkelsen CA, et al: Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20:53-65, 2014
132. Stein EM, Tallman MS: Mixed lineage rearranged leukemia. Curr Opin Hematol 22:92-96, 2015
133. Zuber J, Shi J, Wang E, et al: RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478:524-528, 2011
134. Mussai F, Egan S, Higginbotham-Jones J, et al: Arginine dependence of acute myeloid leukemia blast proliferation: A novel therapeutic target. Blood 125:2386-2397, 2015
135. Lancet JE: A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica 100:231-237, 2015
136. Zwaan CM, Rizzari C, Mechinaud F, et al: Dasatinib in children and adolescents with relapsed or refractory leukemia: Results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol 31:2460-2468, 2013
137. Slats AM, Egeler RM, van der Does-van den Berg A, et al: Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): The Dutch Childhood Oncology Group experience. Leukemia 19: 537-544, 2005
138. Creutzig U, Zimmermann M, Reinhardt D, et al: Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 22: 4384-4393, 2004
139. Sung L, Aplenc R, Alonzo TA, et al: Effectiveness of supportive care measures to reduce infections in pediatric AML: A report from the Children's Oncology Group. Blood 121:3573-3577, 2013
140. Groll AH, Castagnola E, Cesaro S, et al: Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in pediatric patients with cancer or allogeneic hemopoietic stem-cell transplantation. Lancet Oncol 15: e327-e340, 2014
141. Van de Wetering MD, van Woensel JB, Lawrie TA: Prophylactic antibiotics for preventing Grampositive infections associated with long-term central venous catheters in oncology patients. Cochrane Database Syst Rev 11:1-33, 2013
142. Alexander S, Nieder M, Zerr DM, et al: Prevention of bacterial infection in pediatric oncology: What do we know, what can we learn? Pediatr Blood Cancer 59:16-20, 2012
143. Dvorak CC, Fisher BT, Sung L, et al: Antifungal prophylaxis in pediatric hematology/oncology: New choices and new data. Pediatr Blood Cancer 59:21-26, 2012
144. Sung L, Nathan PC, Alibhai SMH, et al: Meta-analysis: Effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 147:400-411, 2007
145. Wheatley K, Goldstone AH, Littlewood T, et al: Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: A study of the United Kingdom Medical Research Council Adult Leukemia Working Party. Br J Haematol 146:54-63, 2009
146. Ehlers S, Herbst C, Zimmermann M, et al: Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol 28:2591-2597, 2010
147. Oberoi S, Lehrnbecher T, Phillips B, et al: Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A systematic review and metaanalysis. Leuk Res 38:460-468, 2014
148. Lehrnbecher T, Phillips R, Alexander S, et al: Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 30:4427-4438, 2012
149. Sung L, Robinson P, Treister N, et al: Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation. BMJ Support Palliat Care doi: 10.1136/ bmjspcare-2014-000804 [epub ahead of print on March 27, 2015]